FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance.

FGF21 combined with leptin reverses hepatic leptin resistance, offering a potent therapy for obesity-related metabolic disorders in mice and human tissues.

• Why it matters: Leptin resistance limits the effectiveness of leptin-based treatments for obesity and its comorbidities, creating a need for strategies that restore leptin sensitivity and improve metabolic health.
• What they did: Researchers used a dual agonist of FGF21 and leptin in mice and examined human liver cells, demonstrating that FGF21 promotes adiponectin secretion, which restores leptin receptor expression and function.
• The result: The dual therapy significantly improved weight, insulin sensitivity, and liver health without reducing food intake, suggesting a promising approach for treating obesity-related conditions through peripheral tissue modulation.